SBRT combined with PD-1/PD-L1 inhibitors in NSCLC treatment: a focus on the mechanisms, advances, and future challenges

Abstract Immune checkpoint inhibitors targeting programmed cell death 1 (PD-1), programmed cell death ligand-1 (PD-L1), and others have shown potent clinical efficacy and have revolutionized the treatment protocols of a broad spectrum of tumor types, especially non–small-cell lung cancer (NSCLC). De...

Cijeli opis

Bibliografski detalji

Glavni autori:	Yu Chen, Min Gao, Zhaoqin Huang, Jinming Yu, Xiangjiao Meng
Format:	Artigo
Jezik:	Inglês
Izdano:	BMC 2020-07-01
Serija:	Journal of Hematology & Oncology
Teme:	Stereotactic body radiation therapy (SBRT) PD-1/PD-L1 inhibitors Combination treatment Non-small-cell lung cancer (NSCLC) Advances Challenges
Online pristup:	http://link.springer.com/article/10.1186/s13045-020-00940-z
Oznake:	Dodaj oznaku Bez oznaka, Budi prvi tko označuje ovaj zapis!